Depression and epilepsy: Do glucocorticoids and glutamate explain their relationship?

Current Neurology and Neuroscience Reports

Volumn 9, Issue 4, 2009, Pages 307-312

  Kanner, Andres M ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; GLUCOCORTICOID; GLUTAMIC ACID; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANXIETY DISORDER; BRAIN ATROPHY; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMORBIDITY; CORTICOTROPIN RELEASE; DEPRESSION; DISEASE ASSOCIATION; DOSE RESPONSE; EPILEPSY; GENERALIZED ANXIETY DISORDER 7; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MAJOR DEPRESSION; MENTAL DISEASE; NEUROLOGICAL DISORDERS DEPRESSION INVENTORY FOR EPILEPSY; NONHUMAN; PATHOGENESIS; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; REVIEW; RISK FACTOR; SUICIDAL IDEATION; TEMPORAL LOBECTOMY; ANIMAL; HYPOPHYSIS ADRENAL SYSTEM; METABOLISM; PATHOPHYSIOLOGY; SUICIDE;

ANIMALS; COMORBIDITY; DEPRESSIVE DISORDER; EPILEPSY; GLUCOCORTICOIDS; GLUTAMIC ACID; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY-ADRENAL SYSTEM; QUALITY OF LIFE; RISK FACTORS; SUICIDE;

EID: 67651225575     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-009-0046-1     Document Type: Review

References (48)

1. Kanner AM, BalabanHv A: Depression in epilepsy: how closely related are these two disorders? Neurology 2002, 58(Suppl5): S27-S39.
2. Tellez-Zenteno JF, Patten SB, Jetté N, et al.: Psychiatric comorbidity in epilepsy: A population-based analysis. Epilepsia 2007, 48:2336-2344.
3. Wiegartz P, Seidenberg M, Woodard A, et al.: Co-morbid psychiatric disorder in chronic epilepsy: Recognition and etiology of depression. Neurology 1999, 53(Suppl2):S3-S8.
4. Kanner AM, Kozak AM, Frey M: The use of sertraline in patients with epilepsy: Is it safe? Epilepsy Behav 2000, 1:100-105.
5. Ettinger AB, Weisbrot DM, Nolan EE, et al.: Symptoms of depression and anxiety in pediatric epilepsy patients. Epilepsia 1998, 39:595-599.
6. de Marinis A, Bustamante F, Asmad C, et al.: Prevalence and underrecognition of depression in patients with epilepsy: The experience of the chilean league against epilepsy [abstract]. Epilepsia 2006. Presented at the annual meeting of the American Epilepsy Society. San Diego; December 2-5, 2006.
7. Mendez MF, Cummings J, Benson D, et al.: Depression in epilepsy. Significance and phenomenology. Arch Neurol 1986, 43:766-770.
8. Gilliam F: Optimizing health outcomes in active epilepsy. Neurology 2002, 58(Suppl 5):S9-S19.
9. Lehrner J, Kalchmayr R, Serles W, et al.: Health-related quality of life (HRQOL), activity of daily living (ADL) and depressive mood disorder in temporal lobe epilepsy patients. Seizure 1999, 8:88-92.
10. Perrine K, Hermann BP, Meador KJ, et al.: The relationship of neuropsychological functioning to quality of life in epilepsy [see comments]. Arch Neurol 1995, 52:997-1003.
11. Gilliam F, Kuzniecky R, Faught E, et al.: Patient-validated content of epilepsy-specific quality-of-life measurement. Epilepsia 1997, 38:233-236.
12. Cramer JA, Blum D, Reed M, Fanning K: The influence of comorbid depression on quality of life for people with epilepsy. Epilepsy Behav 2003, 4:515-521.
13. Cramer JA, Blum D, Fanning K, Reed M: The impact of comorbid depression on health resource utilization in a community sample of people with epilepsy. Epilepsy Behav 2004, 5:337-342.
14. Harris EC, Barraclough B: Suicide as an outcome for mental disorders. A meta-analysis. Arch Neurol 1989, 46:1065-1068.
15. Jones JE, Hermann BP, Barry JJ, et al.: Rates and risk factors for suicide, suicidal ideation, and suicide attempts in chronic epilepsy. Epilepsy Behav 2003, 4:S31-S38.
16. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Translational Sciences, Office of Biostatistics: Statistical Review and Evaluation: Antiepileptic Drugs and Suicidality. Available at http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4372b1-01-FDA.pdf. Accessed May 21, 2009.
17. Hesdorffer DC, Kanner AM: The FDA alert on suicidality and antiepileptic drugs: Fire or false alarm? Epilepsia (in press).
18. Hitiris N, Mohanraj R, Norrie J, et al.: Predictors of pharmacoresistant epilepsy. Epilepsy Res 2007, 75:192-196.
19. Kanner AM, Byrne R, Chicharro A, et al.: A lifetime psychiatric history predicts a worse seizure outcome following temporal lobectomy. Neurology 2009, 72:793-799.
20. Anhoury S, Brown RJ, Krishnamoorthy ES, Trimble MR: Psychiatric outcome after temporal lobectomy: A predictive study. Epilepsia 2000, 41:1608-1615.
21. Forsgren L, Nystrom L: An incident case referent study of epileptic seizures in adults. Epilepsy Res 1999, 6:66-81.
22. Hesdorffer DC, Hauser WA, Annegers JF, et al.: Major depression is a risk factor for seizures in older adults. Ann Neurol 2000, 47:246-249.
23. Hesdorffer DC, Hauser WA, Olafsson E, et al.: Depression and suicidal attempt as risk factor for incidental unprovoked seizures. Ann Neurol 2006, 59:35-41.
24. Kanner AM: Mood disordAr and epilepsy: a neurobiologic perspective of their relationship. Dialogues Clin Neurosci 2008, 10:39-45.
25. Kanner AM: DepressAon in epilepsy: a neurobiologic perspective. Epilepsy Curr 2005, 5:21-27.
26. Kanner AM: Do epilepsy and depression share common pathogenic mechanisms? A look at depression in epilepsy. Clin Neurosc Res 2004, 4:31-37.
27. Charney DS, Berman RM, Miller HL: Treatment of depression. In Textbook of Psychopharmacology, edn 2. Edited by Schatzberg AF, Nemeroff CB. Washington, DC: American Psychiatric Association Press; 1998:705-732.
28. Mazarati AM, Shin D, Kwon YS, et al.: Elevated plasma corticosterone level and depressive behavior in experimental temporal lobe epilepsy. Neurobiol Dis 2009, 34:457-461.
29. Zobel A, Wellmer J, Schulze-Rauschenbach S, et al.: Impairment of inhibitory control of the hypothalamic pituitary adrenocortical system in epilepsy. Eur Arch Psychiatry Clin Neurosci 2004, 254:303-311.
30. Holsboer F: Stress, hypercortisolism and corticosteroid receptors in depression: Implications for therapy. J Affect Disord 2001, 62:77-91.
31. Sheline YI: Brain structural changes associated with depression. In Depression and Brain Dysfunction. Edited by Gilliam F, Kanner AM, Sheline YI. London: Taylor & Francis; 2005:85-104.
32. Sheline YI, Gado MH, Kraemer HC: Untreated depression and hippocampal volume loss. Am J Psychiatry 2003, 160:1516-1518.
33. Lucassen PJ, Muller MB, Holsboer F, et al.: Hippocampal apoptosis in major depression is a minor event and absent from subareas at risk for glucocorticoid overexposure. Am J Pathol 2001, 158:453-468.
34. Sapolsky RM: Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 2000, 57:925-935.
35. Sapolsky RM, Uno H, Rebert CS, Finch CE: Hippocampal damage associated with prolonged glucocorticoid exposure in primates. J Neurosci 1990, 10:2897-2902.
36. Smith MA, Makino S, Kvetnansky R, Post RM: Effects of stress on neurotrophic factor expression in the rat brain. Ann N Y Acad Sci 1995, 771:234-239.
37. Nibuya M, Morinobu S, Duman RS: Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995, 15:7539-7547.
38. Chen B, Dowlatshahi D, MacQueen GM, et al.: Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001, 50:260-265.
39. Scimemi A, Schorge S, Kullmann DM, Walker MC: Epileptogenesis is associated with enhanced glutamatergic transmission in the perforant path. J Neurophysiol 2006, 95:1213-1220.
40. Del Rio J, Frechilla D: Glutamate and depression. In Dopamine and Glutamate in Psychiatric Disorders. Edited by Schmidt WE, Reith MAE. Totowa, NJ: Humana Press; 2005:215-233.
41. Tatarczynska E, Klodzinska A, Chojnacka-Wojcik E, et al.: Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol 2001, 132:1423-1430.
42. Tatarczynska E, Palucha A, Szewczyk B, et al.: Anxiolyticand antidepressant-like effects of group III metabotropic glutamate agonist (1S,3R,4S)-1-aminocyclopentane-1,3,4-tricarboxylic acid (ACPT-I) in rats. Pol J Pharmacol 2002, 54:707-710.
43. Berman RM, Cappiello A, Anand A, et al.: Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000, 47:351-354.
44. Baram TZ, Mitchell WG, Brunson K, Haden E: Infantile spasms: hypothesis-driven therapy and pilot human infant experiments using corticotropin-releasing hormone receptor antagonists. Dev Neurosci 1999, 21:281-289.
45. Wang W, Dow KE, Fraser DD: Elevated corticotropin releasing hormone/ corticotropin releasing hormone-R1 expression in postmortem brain obtained from children with generalized epilepsy. Ann Neurol 2001, 50:404-409.
46. Gilliam FG, Barry JJ, Hermann BP, et al.: Rapid detection of major depression in epilepsy: A multicentre study. Lancet Neurol 2006, 5:399-405
47. Kroenke K, Spitzer RL, Williams JB, et al.: Anxiety disorders in primary care: Prevalence, impairment, comorbidity, and detection. Ann Intern Med 2007, 146:317-325.
48. Sheehan BV, Lecrubier Y, Sheehan KH, et al.: The Mini International Neuropsychiatric Interview (MINI): The development and validation of structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998, 59(Suppl 20): 22-33.